Bosentas 125mg

Bosentas 125mg is a non-selective antagonist of endothelin receptors. The drug is approved for the treatment of diseases such as pulmonary arterial hypertension in patients of 2-4 functional class (according to the classification of WHO). The drug is able to reduce the number of new digital ulcers in adult patients suffering from systemic scleroderma and progressive ulcerative lesions of the limbs.
Studies have shown that the use of Bosentas 125mg with standard therapy (along with anticoagulants, vasodilators, diuretics, digoxin, but not epoprostenol) causes an increase in tolerance to exercise. The positive effect was achieved on the 4th week of treatment. Improvements became apparent after 8 weeks of therapy. The positive effect was maintained for 28 weeks of treatment. The group of patients, who received Bosentas 125mg, noticed the decrease of the severity of symptoms of pulmonary arterial hypertension. Studies have shown that Bosentas increases the cardiac index, significantly reduces the pressure in the pulmonary artery, as well as reduces pulmonary vascular resistance and average pressure in the right atrium.

Method of reception and dosage

The drug is taken orally in the morning and evening with water, regardless of meal.
The pills shouldn’t be chewed.
The initial dose for patients with pulmonary arterial hypertension is 62.5 mg twice a day for four weeks. In the future, the dose is increased to 125 mg twice a day.
If a dose of 125 mg hasn’t given the desired effect, you can increase it to 250 mg twice a day. At the same time, it is important to remember the negative dose-dependent effect of Bosentas 125mg on the liver and make the appropriate decisions, relating the potential risk and the expected benefit.
If you want to prevent withdrawal syndrome, it is necessary to reduce the dose gradually (at half, in the period from three to seven days) and at the same time you should start alternative therapy.
The initial dose of Bosentas 125mg for patients suffering from systemic scleroderma and progressive ulcerative lesions of the limbs is 62.5 mg twice a day for four weeks. In the future, the dose is increased to 125 mg twice a day.
Do not use Bosentas 125mg in case of moderate and severe hepatic impairment.
The dose for patients weighing less than 40 kilograms, as well as for children, is calculated taking into account body weight.